Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

BioNTech executive says it is too early to predict China vaccine approval

Published 11/07/2022, 10:05 AM
Updated 11/07/2022, 02:47 PM
© Reuters. FILE PHOTO: Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration

FRANKFURT (Reuters) - A BioNTech executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory approval of the German biotech firm's COVID-19 vaccine for use by expatriates in China but the outcome was uncertain.

"We have seen some positive re-engagement, as has been reported. We confirm that we have been taking part in some discussions, which are very positive," Chief Strategy Officer Ryan Richardson said in an analyst call.

© Reuters. FILE PHOTO: Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration

He added it was too early to predict the extent or the timing of such an approval for foreigners working in China.

BioNTech shares rose on Friday after German Chancellor Olaf Scholz announced an agreement to let expatriates in China use the vaccine and he pressed for Beijing to allow the shot to be made freely available to Chinese citizens.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.